Court Orders BardyDx Merger to Go Forward, but Hillrom Plans to Appeal

Hillrom wanted to opt-out of acquiring Bardy Diagnostics because it claimed Medicare rate cuts for long-term cardiac monitoring constituted a material adverse event to the merger agreement.